AR012255A1 - Sal tartrato de un dipeptido sustituido - Google Patents
Sal tartrato de un dipeptido sustituidoInfo
- Publication number
- AR012255A1 AR012255A1 ARP980103022A ARP980103022A AR012255A1 AR 012255 A1 AR012255 A1 AR 012255A1 AR P980103022 A ARP980103022 A AR P980103022A AR P980103022 A ARP980103022 A AR P980103022A AR 012255 A1 AR012255 A1 AR 012255A1
- Authority
- AR
- Argentina
- Prior art keywords
- useful
- acid salt
- tartaric acid
- growth hormone
- osteoporosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
Abstract
Sal del ácido (L) tartárico de la 2-amino-N-{1-(2,4-difluoro- benciloximetil)-2-oxo-2-(3-oxo-3a-piridin-2-ilmetil-2-(2,2,2-trifluoro-etil)-2,3,3a,4,6,7-hexahidro-pirazolo(4,3-c)piridin-5-il)etil}-2-metil-propionamida, la cual es un secretagogo de la hormona del crecimiento y como tal, es utilpara aumentar el nivel de hormona del crecimiento endogena. En otro aspecto, determinados productos intermedios son utiles para la síntesis delcompuesto anterior. La sal del ácido (L)-tartárico es util para el tratamiento y/o prevencion de la osteoporosis, resistencia a la insulina y otrostrastornos o enfermedades asociados con la deficiencia de hormona del crecimiento. La sal del ácido (L)-tartárico es también util para eltratamiento de la osteoporosis cuando se usa en combinacion con un compuesto bisfosfonato, estrogenos, Premarin y opcionalmente progesterona, un agonistao antagonista de estrogenos o calcitonina. Además, composiciones farmacéuticas, procedimientosque comprenden la administracion a un ser humano u a otro animalde una combinacion de un agonista alfa-2-adrenérgico y de la sal del ácido (L)-tartárico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5072397P | 1997-06-25 | 1997-06-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR012255A1 true AR012255A1 (es) | 2000-09-27 |
Family
ID=21966996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980103022A AR012255A1 (es) | 1997-06-25 | 1998-06-23 | Sal tartrato de un dipeptido sustituido |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US6248717B1 (es) |
| EP (1) | EP0989993B1 (es) |
| JP (1) | JP3414759B2 (es) |
| KR (1) | KR100339936B1 (es) |
| CN (2) | CN1524857A (es) |
| AP (1) | AP1043A (es) |
| AR (1) | AR012255A1 (es) |
| AT (1) | ATE388163T1 (es) |
| AU (1) | AU744775B2 (es) |
| BG (1) | BG104024A (es) |
| BR (1) | BR9810623B1 (es) |
| CA (1) | CA2294422C (es) |
| CO (1) | CO4810383A1 (es) |
| DE (1) | DE69839211T2 (es) |
| DK (1) | DK0989993T3 (es) |
| DZ (1) | DZ2538A1 (es) |
| EA (1) | EA002643B1 (es) |
| ES (1) | ES2301196T3 (es) |
| GT (1) | GT199800085A (es) |
| HR (1) | HRP980362A2 (es) |
| HU (1) | HUP0002664A3 (es) |
| ID (1) | ID23188A (es) |
| IL (1) | IL132810A0 (es) |
| IS (1) | IS5276A (es) |
| MA (1) | MA26516A1 (es) |
| NO (1) | NO996469L (es) |
| NZ (1) | NZ500658A (es) |
| OA (1) | OA11241A (es) |
| PA (1) | PA8453401A1 (es) |
| PE (1) | PE97599A1 (es) |
| PL (1) | PL337654A1 (es) |
| PT (1) | PT989993E (es) |
| SK (1) | SK177299A3 (es) |
| TN (1) | TNSN98111A1 (es) |
| TR (1) | TR199903261T2 (es) |
| TW (1) | TWI221153B (es) |
| UA (1) | UA53716C2 (es) |
| UY (1) | UY25059A1 (es) |
| WO (1) | WO1998058948A1 (es) |
| ZA (1) | ZA985541B (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
| UA64751C2 (uk) | 1997-06-25 | 2004-03-15 | Пфайзер Продактс Інк. | Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти) |
| UA53716C2 (uk) | 1997-06-25 | 2003-02-17 | Пфайзер Продактс Інк. | Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти) |
| US6465445B1 (en) * | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
| US6380184B1 (en) | 1998-10-28 | 2002-04-30 | Bristol-Myers Squibb Co. | Benzoazepines and analogs thereof useful as growth hormone secretagogues |
| AU759022B2 (en) | 1999-02-18 | 2003-04-03 | Kaken Pharmaceutical Co., Ltd. | Novel amide derivatives as growth hormone secretagogues |
| US6541634B2 (en) * | 1999-02-26 | 2003-04-01 | Pfizer Inc. | Process for preparing growth hormone secretagogues |
| US6525203B1 (en) | 1999-03-12 | 2003-02-25 | Bristol-Myers Squibb Company | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| US6518292B1 (en) | 1999-03-12 | 2003-02-11 | Bristol-Myers Squibb Co. | Heterocyclic aromatic compounds usefuls as growth hormone secretagogues |
| US20020013327A1 (en) * | 2000-04-18 | 2002-01-31 | Lee Andrew G. | Compositions and methods for treating female sexual dysfunction |
| ATE310728T1 (de) | 2000-05-11 | 2005-12-15 | Bristol Myers Squibb Co | Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga |
| AU6497701A (en) | 2000-05-30 | 2001-12-11 | Merck & Co Inc | Melanocortin receptor agonists |
| EP1159964B1 (en) * | 2000-05-31 | 2009-10-28 | Pfizer Products Inc. | Use of growth hormone secretagogues for stimulating gastrointestinal motility |
| IL143690A0 (en) * | 2000-06-19 | 2002-04-21 | Pfizer Prod Inc | The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease |
| IL143942A0 (en) * | 2000-06-29 | 2002-04-21 | Pfizer Prod Inc | Use of growth hormone secretagogues for treatment of physical performance decline |
| EP1181933A3 (en) * | 2000-06-29 | 2002-04-10 | Pfizer Products Inc. | Use of growth hormone secretagogues for stimulating or increasing appetite |
| IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
| BR0113626A (pt) * | 2000-08-30 | 2003-06-17 | Pfizer Prod Inc | Formulações de liberação sustentada para secretores de hormÈnio do crescimento |
| EP1192943A3 (en) * | 2000-09-28 | 2002-11-27 | Pfizer Products Inc. | Use of growth hormone secretagogues in conjunction with physical exercise |
| CN1469871A (zh) * | 2000-10-13 | 2004-01-21 | 作为生长激素促分泌素的取代的二肽 | |
| CA2372450A1 (en) * | 2001-05-10 | 2001-09-19 | Pharmaceutical Partners Of Canada Inc. | Liquid injectable formulation of disodium pamidronate |
| US7125840B2 (en) | 2001-10-09 | 2006-10-24 | Eli Lilly And Company | Substituted dipeptides as growth hormone secretagogues |
| AU2002357692A1 (en) | 2001-11-09 | 2003-05-26 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity |
| US7396846B2 (en) | 2002-04-09 | 2008-07-08 | Eli Lilly And Company | Growth hormone secretagogues |
| US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| WO2005027913A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue |
| EP1789409A4 (en) * | 2004-04-02 | 2010-09-08 | Elixir Pharmaceuticals Inc | SULPHONAMIDES AND ITS USES |
| KR100641571B1 (ko) * | 2005-01-05 | 2006-10-31 | 주식회사 팬택앤큐리텔 | 이동통신 단말기에서의 클럭 발생 장치 |
| CU23558A1 (es) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento |
| EA200901077A1 (ru) | 2007-02-09 | 2010-04-30 | Транзим Фарма, Инк. | Макроциклические модуляторы грелинового рецептора и их применение |
| US8377863B2 (en) | 2007-05-29 | 2013-02-19 | Unigene Laboratories Inc. | Peptide pharmaceutical for oral delivery |
| EP2721048A1 (en) * | 2011-06-16 | 2014-04-23 | Lonza Ltd | A process for extraction of peptides and its application in liquid phase peptide synthesis |
| US9949992B2 (en) * | 2011-11-16 | 2018-04-24 | Duke University | Bisphosphonate compositions and methods for treating and\or reducing cardiac dysfunction |
| US9119832B2 (en) | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
| WO2016115082A1 (en) | 2015-01-12 | 2016-07-21 | Enteris Biopharma, Inc. | Solid oral dosage forms |
| US20170121385A1 (en) | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4411890A (en) | 1981-04-14 | 1983-10-25 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
| CA2147503A1 (en) | 1992-11-06 | 1994-05-26 | Judith M. Pisano | Substituted dipeptide analogs promote release of growth hormone |
| RO115804B1 (ro) | 1992-12-11 | 2000-06-30 | Merck & Co Inc | Derivati de spiropiperidine, procedee de preparare si compozitii farmaceutice ale acestora |
| CZ134296A3 (en) | 1993-11-09 | 1996-12-11 | Merck & Co Inc | Piperidine, pyrrolidine and hexahydro-1h-azepine derivatives, process of their preparation and pharmaceutical compositions containing thereof |
| TW432073B (en) | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| UA64751C2 (uk) | 1997-06-25 | 2004-03-15 | Пфайзер Продактс Інк. | Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти) |
| UA53716C2 (uk) | 1997-06-25 | 2003-02-17 | Пфайзер Продактс Інк. | Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти) |
| GT199800127A (es) | 1997-08-29 | 2000-02-01 | Combinaciones terapeuticas. |
-
1998
- 1998-05-06 UA UA99127067A patent/UA53716C2/uk unknown
- 1998-06-05 ID IDW991663A patent/ID23188A/id unknown
- 1998-06-05 EA EA199901076A patent/EA002643B1/ru not_active IP Right Cessation
- 1998-06-05 NZ NZ500658A patent/NZ500658A/en unknown
- 1998-06-05 AU AU74455/98A patent/AU744775B2/en not_active Ceased
- 1998-06-05 US US09/380,886 patent/US6248717B1/en not_active Expired - Lifetime
- 1998-06-05 IL IL13281098A patent/IL132810A0/xx unknown
- 1998-06-05 KR KR1019997012222A patent/KR100339936B1/ko not_active IP Right Cessation
- 1998-06-05 DE DE69839211T patent/DE69839211T2/de not_active Expired - Lifetime
- 1998-06-05 TR TR1999/03261T patent/TR199903261T2/xx unknown
- 1998-06-05 BR BRPI9810623-6A patent/BR9810623B1/pt not_active IP Right Cessation
- 1998-06-05 DK DK98921681T patent/DK0989993T3/da active
- 1998-06-05 CN CNA2004100059410A patent/CN1524857A/zh active Pending
- 1998-06-05 CA CA002294422A patent/CA2294422C/en not_active Expired - Lifetime
- 1998-06-05 WO PCT/IB1998/000874 patent/WO1998058948A1/en active IP Right Grant
- 1998-06-05 PT PT98921681T patent/PT989993E/pt unknown
- 1998-06-05 CN CN98806559A patent/CN1314912A/zh active Pending
- 1998-06-05 SK SK1772-99A patent/SK177299A3/sk unknown
- 1998-06-05 ES ES98921681T patent/ES2301196T3/es not_active Expired - Lifetime
- 1998-06-05 AT AT98921681T patent/ATE388163T1/de not_active IP Right Cessation
- 1998-06-05 HU HU0002664A patent/HUP0002664A3/hu unknown
- 1998-06-05 EP EP98921681A patent/EP0989993B1/en not_active Expired - Lifetime
- 1998-06-05 JP JP50402799A patent/JP3414759B2/ja not_active Expired - Fee Related
- 1998-06-05 PL PL98337654A patent/PL337654A1/xx unknown
- 1998-06-11 PA PA19988453401A patent/PA8453401A1/es unknown
- 1998-06-18 GT GT199800085A patent/GT199800085A/es unknown
- 1998-06-18 AP APAP/P/1998/001266A patent/AP1043A/en active
- 1998-06-19 PE PE1998000540A patent/PE97599A1/es not_active Application Discontinuation
- 1998-06-22 TW TW087110024A patent/TWI221153B/zh not_active IP Right Cessation
- 1998-06-23 UY UY25059A patent/UY25059A1/es not_active IP Right Cessation
- 1998-06-23 AR ARP980103022A patent/AR012255A1/es not_active Application Discontinuation
- 1998-06-24 DZ DZ980148A patent/DZ2538A1/xx active
- 1998-06-24 MA MA25138A patent/MA26516A1/fr unknown
- 1998-06-24 TN TNTNSN98111A patent/TNSN98111A1/fr unknown
- 1998-06-25 ZA ZA9805541A patent/ZA985541B/xx unknown
- 1998-06-25 HR HR60/050,723A patent/HRP980362A2/hr not_active Application Discontinuation
- 1998-06-25 CO CO98036378A patent/CO4810383A1/es unknown
-
1999
- 1999-11-26 IS IS5276A patent/IS5276A/is unknown
- 1999-12-16 BG BG104024A patent/BG104024A/bg unknown
- 1999-12-21 OA OA9900299A patent/OA11241A/en unknown
- 1999-12-23 NO NO996469A patent/NO996469L/no not_active Application Discontinuation
-
2000
- 2000-12-11 US US09/734,269 patent/US6596867B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR012255A1 (es) | Sal tartrato de un dipeptido sustituido | |
| JP3842987B2 (ja) | 胃腸運動を刺激するための組成物及び方法 | |
| ES2321620T3 (es) | Combinacion que comprende n-(3-metoxi-5-metilpirazin-2-il)-2-(4-(1,3,4-oxadiazol-2-il)fenil)piridina-3-sulfonamida y un bifosfonato. | |
| MY144897A (en) | 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists | |
| US20090143415A1 (en) | Tetrodotoxin And Its Derivatives For The Treatment Of Central-Nervously Derived Neuropathic Pain | |
| HUP0105173A2 (hu) | Adagolási módszer és készítmény sürgősségi fogamzásgátlásra | |
| EA200500985A1 (ru) | Твердая лекарственная форма для перорального применения | |
| US20020013320A1 (en) | Use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease | |
| CN105072909A (zh) | 应用控制食欲不振的化合物的组合物和方法 | |
| JP2002060348A (ja) | 身体機能低下の治療のための成長ホルモン分泌促進物質の使用 | |
| CUTLER JR et al. | Pubertal growth: physiology and pathophysiology | |
| US20220362328A1 (en) | Uses of bremelanotide in therapy for female sexual dysfunction | |
| US20040220094A1 (en) | Inverse agonist and agonist peptides that stimulate/inhibit hair growth | |
| US20170304406A1 (en) | New indication for alpha-msh analogues | |
| EP2162129B1 (en) | Use of hdac inhibitors for the treatment of bone destruction | |
| TR200201503T2 (tr) | Heterosiklik türevler. | |
| ECSP982523A (es) | Sal tartrato de un dipeptido sustituido | |
| Nargund et al. | Growth hormone secretagogues | |
| KR102494794B1 (ko) | 여성 성기능장애의 치료를 위한 약학 조성물 및 방법 | |
| TH45376A (th) | เกลือตาร์เตรทของไดเพปไทด์ที่ถูกแทนที่ | |
| BG102476A (en) | Polymorphous forms of secretagogue of growth hormone | |
| NZ226816A (en) | Parenteral formulation comprising somatotropin, m-cresol and glycerin | |
| Whitfield et al. | CYCLASE-PARATHYROID A PROSTAGLANDINS NABOLIC HORMONE A | |
| Joseph | Effects of injection of mepesulphate into the cerebral ventricles of cats | |
| Clark | GHRP Structure–Activity Relationship: An In Vivo Perspective |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |